Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM1A | O60341 | 4/20 | 0.37 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.36 |
| ▸ | CDK2 | P24941 | 4/20 | 0.36 |
| ▸ | CHUK | O15111 | 1/20 | 0.36 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.36 |
| ▸ | MCHR1 | Q99705 | 2/20 | 0.35 |
| ▸ | EP300 | Q09472 | 6/20 | 0.35 |
| ▸ | CCNA2 | P20248 | 3/20 | 0.35 |
| ▸ | CCNA1 | P78396 | 3/20 | 0.35 |
| ▸ | CDK1 | P06493 | 2/20 | 0.35 |
| ▸ | CCNB1 | P14635 | 2/20 | 0.35 |
| ▸ | CCNB2 | O95067 | 1/20 | 0.34 |
| ▸ | MAPK3 | P27361 | 1/20 | 0.34 |
| ▸ | CLK1 | P49759 | 1/20 | 0.34 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.34 |
| ▸ | PIN1 | Q13526 | 1/20 | 0.34 |
| ▸ | CCNB3 | Q8WWL7 | 1/20 | 0.34 |
| ▸ | MAP3K5 | Q99683 | 1/20 | 0.34 |
| ▸ | RHEB | Q15382 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4445675 | 0.93 | FFAR4 (0.39) | KDM1ACDK2CHUKFFAR4EP300 | |
| SCHEMBL31080672 | 0.86 | ATXN2 (0.41) | KDM1AFFAR4EP300 | |
| SCHEMBL7209219 | 0.77 | IDO1 (0.37) | CDK2MCHR1CCNA2CCNA1CDK1 | |
| SCHEMBL31080336 | 0.76 | PDCD1 (0.40) | KDM1AEP300 | |
| SCHEMBL19510571 | 0.74 | PDGFRB (0.43) | KDM4CCDK2FFAR4 | |
| SCHEMBL30338856 | 0.74 | KDM4C (0.42) | KDM4CCDK2CHUKCCNA2CCNA1 | |
| SCHEMBL30350762 | 0.73 | MCHR1 (0.48) | KDM1ACDK2FFAR4MCHR1CCNA2 | |
| SCHEMBL19510612 | 0.73 | MCHR1 (0.48) | KDM1ACDK2FFAR4MCHR1CCNA2 | |
| SCHEMBL31080120 | 0.73 | FEN1 (0.47) | KDM1A | |
| SCHEMBL3509188 | 0.73 | SIGMAR1 (0.46) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1335907-B1 | PIPERAZINYLPYRAZINE COMPOUNDS AS AGONIST OR ANTAGONIST OF SEROTONIN 5HT-2 RECEPTOR | BIOVITRUM AB PUBL (SE) | 2010-06-09 | — | — | EP | disclosed |
| US-7247633-B2 | Pyrimidine compounds and their use | BIOVITRUM AB (SE) | 2007-07-24 | — | — | US | disclosed |
| US-20040014767-A1 | Novel compounds and their use | BIOVITRUM AB, A SWEDISH CORPORATION | 2004-01-22 | — | — | US | disclosed |
| EP-1335907-A1 | PIPERAZINYLPYRAZINE COMPOUNDS AS AGONIST OR ANTAGONIST OF SEROTONIN 5HT-2 RECEPTOR | BIOVITRUM AB (SE) | 2003-08-20 | — | — | EP | disclosed |
| US-6593330-B2 | Central nervous system disorders; antiserotonine agents | BIOVITRUM (SE) | 2003-07-15 | — | — | US | disclosed |
| US-20020147200-A1 | Novel compounds and their use | PROXIMAGEN NEUROSCIENCE PLC (GB) | 2002-10-10 | — | — | US | disclosed |
| WO-2002040456-A1 | PIPERAZINYLPYRAZINE COMPOUNDS AS AGONIST OR ANTAGONIST OF SEROTONIN 5HT-2 RECEPTOR | BIOVITRUM AB (SE) | 2002-05-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020147200-A1 | Novel compounds and their use | BRIX1, UGT1A1, NR5A1 | KDM1A 1412/4885KDM4C 2201/4885CDK2 602/4885 |
| US-20040014767-A1 | Novel compounds and their use | BRIX1, UGT1A1, NR5A1 | KDM1A 1412/4885KDM4C 2201/4885CDK2 602/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.